Compare CWST & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWST | WGS |
|---|---|---|
| Founded | 1975 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Environmental Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Utilities | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 2.6B |
| IPO Year | 1997 | N/A |
| Metric | CWST | WGS |
|---|---|---|
| Price | $95.78 | $94.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $118.75 | ★ $140.71 |
| AVG Volume (30 Days) | ★ 828.9K | 738.9K |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $1,836,841,000.00 | N/A |
| Revenue This Year | $10.03 | $29.98 |
| Revenue Next Year | $6.48 | $24.85 |
| P/E Ratio | ★ $788.92 | $1,251.58 |
| Revenue Growth | ★ 17.95 | N/A |
| 52 Week Low | $82.22 | $55.17 |
| 52 Week High | $121.20 | $170.87 |
| Indicator | CWST | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 46.67 | 55.19 |
| Support Level | $93.68 | $78.80 |
| Resistance Level | $103.61 | $95.94 |
| Average True Range (ATR) | 3.68 | 5.77 |
| MACD | 0.10 | 2.18 |
| Stochastic Oscillator | 48.29 | 97.99 |
Casella Waste Systems Inc is a solid waste removal company, providing resource management services to residential, commercial, municipal, and industrial customers. The company's reportable segments on Geographical basis include Eastern, Western and Mid-Atlantic regions through the Resource solution segment. It generates maximum revenue from the Western region segment. The company's services include Recycling, Collection, Organics, Energy, Landfills, Special Waste as well as Professional Services.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.